Premium
Serum‐soluble interleukin‐2 receptors in neuroleptic‐naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia
Author(s) -
Rapaport M. H.,
Lohr J. B.
Publication year - 1994
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1994.tb01599.x
Subject(s) - tardive dyskinesia , dyskinesia , psychosis , schizophrenia (object oriented programming) , psychology , medicine , endocrinology , psychiatry , parkinson's disease , disease
There is a growing body of literature suggesting that some schizophrenic subjects have evidence of immune activation. One marker that has been consistently elevated in studies is the serum‐soluble interleukin‐2 receptor (SIL‐2R). This article reports the results of 2 experiments: the first compares concentrations of serum SIL‐2R in neuroleptic‐naive schizophrenic patients and matched controls, and the second study contrasts serum SIL‐2R concentrations in medicated schizophrenic subjects with and without tardive dyskinesia. Serum SIL‐2R concentrations were elevated in neuroleptic‐naive schizophrenic subjects as compared with controls (1705.7 (SD 1124.2) U/ml vs 739.8 (SD 325.5) U/ml). Medicated subjects with tardive dyskinesia had increased serum SIL‐2R levels (2385.5 (SD 1822.0) U/ml) compared with medicated subjects without tardive dyskinesia (1259.6 (SD 1365.3) U/ml). Thus, elevations in serum SIL‐2R levels are present prior to neuroleptic treatment, and there may be an association between serum SIL‐2Rs and tardive dyskinesia.